Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin J Boeree

Showing results (111-120 of 123) with videos related to

Pageof 13
Sort By:
Trials|January 30, 2026
A pragmatic trial with an optimized dose of rifampicin and moxifloxacin for the treatment of drug-susceptible pulmonary tuberculosis: a study protocol for open-label, randomized phase III trial (OptiRiMoxTB)Hamu J Mlyuka, Alphonce Liyoyo, Belinda Nyaulingo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2018
The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary TuberculosisElin M Svensson, Robin J Svensson, Lindsey H M Te Brake, et al.
The Lancet. Respiratory Medicine|January 28, 2014
Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational studyJosephine M Bryant, Simon R Harris, Julian Parkhill, et al.
The Lancet. Microbe|January 10, 2025
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trialNorbert Heinrich, Veronique de Jager, Julia Dreisbach, et al.
The Lancet. Infectious Diseases|March 3, 2023
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statementJosé Domínguez, Martin J Boeree, Emmanuelle Cambau, et al.
Journal of Clinical Pharmacology|September 23, 2021
Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic ModelingCarlijn H C Litjens, Laurens F M Verscheijden, Celine Bolwerk, et al.
Thorax|May 2, 2020
Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load AssayWilber Sabiiti, Khalide Azam, Eoghan Charles William Farmer, et al.
The Lancet. Infectious Diseases|January 20, 2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trialMartin J Boeree, Norbert Heinrich, Rob Aarnoutse, et al.
The Lancet. Infectious Diseases|July 11, 2025
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trialLilian Tina Minja, Isabella van der Feltz, Christina Manyama, et al.
The European Respiratory Journal|April 20, 2013
The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative studyWouter Hoefsloot, Jakko van Ingen, Claire Andrejak, et al.
Pageof 13

Showing results (111-120 of 123) with videos related to

Sort By:
Pageof 13
Trials|January 30, 2026
A pragmatic trial with an optimized dose of rifampicin and moxifloxacin for the treatment of drug-susceptible pulmonary tuberculosis: a study protocol for open-label, randomized phase III trial (OptiRiMoxTB)Hamu J Mlyuka, Alphonce Liyoyo, Belinda Nyaulingo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2018
The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary TuberculosisElin M Svensson, Robin J Svensson, Lindsey H M Te Brake, et al.
The Lancet. Respiratory Medicine|January 28, 2014
Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational studyJosephine M Bryant, Simon R Harris, Julian Parkhill, et al.
The Lancet. Microbe|January 10, 2025
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trialNorbert Heinrich, Veronique de Jager, Julia Dreisbach, et al.
The Lancet. Infectious Diseases|March 3, 2023
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statementJosé Domínguez, Martin J Boeree, Emmanuelle Cambau, et al.
Journal of Clinical Pharmacology|September 23, 2021
Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic ModelingCarlijn H C Litjens, Laurens F M Verscheijden, Celine Bolwerk, et al.
Thorax|May 2, 2020
Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load AssayWilber Sabiiti, Khalide Azam, Eoghan Charles William Farmer, et al.
The Lancet. Infectious Diseases|January 20, 2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trialMartin J Boeree, Norbert Heinrich, Rob Aarnoutse, et al.
The Lancet. Infectious Diseases|July 11, 2025
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trialLilian Tina Minja, Isabella van der Feltz, Christina Manyama, et al.
The European Respiratory Journal|April 20, 2013
The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative studyWouter Hoefsloot, Jakko van Ingen, Claire Andrejak, et al.
Pageof 13